Chemotherapy delivered directly to abdomen shows promise in early trial
NCT ID NCT01061515
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a combination of three drugs for people whose appendix or colon cancer has spread to the lining of the abdomen (peritoneal carcinomatosis). After surgery to remove visible tumors, patients receive chemotherapy directly into the abdomen (oxaliplatin) plus oral and intravenous drugs (capecitabine and bevacizumab). The main goal is to find the safest dose and check for side effects in 21 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oxaliplatin (chemotherapy), capecitabine (chemotherapy), bevacizumab (targeted therapy)
- What this could lead to
- If this works, it could point toward a more effective way to deliver chemotherapy directly to the abdomen for people with advanced abdominal cancers, potentially improving survival.
- What could go wrong
- This is a very early (Phase 1) trial with only 21 participants, so it is primarily testing safety and dosing, not effectiveness. The combination may cause significant side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Could your workout history affect your Cancer's genes?
- New combo therapy aims to stop liver cancer from coming back
- New drug combo takes on advanced cancers in early trial